SONR : CLEAR STUDY DEMONSTRATES AUTOMATIC OPTIMIZATION OF CRT WITH SONR IMPROVES HEART FAILURE PATIENTS RESPONSE RATES
EDIT 2011-10-12 : News from SonR here
Sorin Group’s exclusive SonR sensor technology improves responder rates for heart failure patients through the regular automatic optimization of CRT
Paris, France, June 17, 2010 – Sorin Group (Reuters Code: SORIN.MI), a global leader in the treatment of cardiovascular diseases, announced today that the CLEAR study has met its primary endpoint.
The CLEAR study, with 156 patients enrolled in 51 centers in 8 countries, is sponsored exclusively by Sorin Group. The study demonstrates reduced mortality and heart failure (HF) related hospitalization in patients whose cardiac resynchronization therapy was optimized on a regular basis.
Sorin Group’s SonR technology consists of a sensor embedded in the tip of a pacing lead implanted with a CRT device. The sensor measures real-time cardiac contractility and the CRT device utilizes this hemodynamic data to regularly optimize the therapy delivered.
Final results show that regular optimization of CRT patients using Sorin Group’s SonR sensor technology improves clinical response rate to 86%, compared to 62%, in patients receiving standard medical treatment. (p=0.0013).
Patients in sinus rhythm and with severe heart failure, New York Heart Association (NYHA) Class III and IV, were enrolled in the CLEAR study. The CLEAR study Steering Committee expects to present and publish the trial's full results later this year.
The CLEAR study was a prospective, multicenter, randomized, single-blind study conducted over the course of 1 year under the leadership of Principal Investigator, Dr. Philippe Ritter, University of Bordeaux, France.
“The results of the CLEAR study are very encouraging as they demonstrate regular automatic optimization significantly increases the responder rate of HF patients by improving hemodynamic performance” said Dr. Philippe Ritter. “The SonR system is capable of automatically optimizing CRT pacing intervals regularly and has the potential of reducing time-consuming ECHO procedures associated with CRT optimization,” he added.
“The CLEAR study results demonstrate that regular optimization of CRT with our innovative SonR technology improves patient outcomes,” said Stefano Di Lullo, President of the Sorin Group CRM business unit. “This is a giant step forward in improving heart failure patient care and a reflection of our commitment to innovation in the hemodynamic management of heart failure patients.”
About the Sorin Group
The Sorin Group (www.sorin.com), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,600 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.
For more information contact:
Director, Corporate Communications
Tel: +33 (0)1 46 01 33 78
Mobile: +33 (0)6 76 12 67 73/+3902438114218
Tel: +39 02 69969716
Tel. + 39 02 89011300